| Title | Loss of Heterozygosity (LOH) Profiles—Validated Risk Predictors for Progression to Oral Cancer |
| Publication Type | Journal Article |
| Year of Publication | 2012 |
| Authors | Zhang, L, Poh, CF, Williams, M, Laronde, DM, Berean, K, Gardner, PJ, Jiang, H, WU, LANG, J. Lee, J, Rosin, MP |
| Journal | Cancer Prevention Research |
| Volume | 5 |
| Pagination | 1081–1089 |
| Date Published | sep |
| ISSN | 1940-6207, 1940-6215 |
| Abstract | A major barrier to oral cancer prevention has been the lack of validated risk predictors for oral premalignant lesions (OPL). In 2000, we proposed a loss of heterozygosity (LOH) risk model in a retrospective study. This paper validated the previously reported LOH profiles as risk predictors and developed refined models via the largest longitudinal study to date of low-grade OPLs from a population-based patient group. Analysis involved a prospective cohort of 296 patients with primary mild/moderate oral dysplasia enrolled in the Oral Cancer Prediction Longitudinal Study. LOH status was determined in these OPLs. Patients were classified into high-risk or low-risk profiles to validate the 2000 model. Risk models were refined using recursive partitioning and Cox regression analyses. The prospective cohort validated that the high-risk lesions (3p and/or 9p LOH) had a 22.6-fold increase in risk (P = 0.002) compared with low-risk lesions (3p and 9p retention). Addition of another 2 markers (loci on 4q/17p) further improved the risk prediction, with five-year progression rates of 3.1%, 16.3%, and 63.1% for the low-, intermediate-, and high-risk lesions, respectively. Compared with the low-risk group, intermediate- and high-risk groups had 11.6-fold and 52.1-fold increase in risk (P < 0.001). LOH profiles as risk predictors in the refined model were validated in the retrospective cohort. Multicovariate analysis with clinical features showed LOH models to be the most significant predictors of progression. LOH profiles can reliably differentiate progression risk for OPLs. Potential uses include increasing surveillance for patients with elevated risk, improving target intervention for high-risk patients while sparing a large number of low-risk patients from needless screening and treatment. Cancer Prev Res; 5(9); 1081–9. ©2012 AACR. |
| URL | http://cancerpreventionresearch.aacrjournals.org/content/5/9/1081 |
| DOI | 10.1158/1940-6207.CAPR-12-0173 |
